<DOC>
	<DOCNO>NCT02285504</DOCNO>
	<brief_summary>This open-label proof-of-concept study design evaluate safety , tolerability , PK , efficacy SAGE-547 Injection adult female patient diagnose severe postpartum depression ( PPD ) .</brief_summary>
	<brief_title>Evaluate SAGE-547 Female Patients With Severe Postpartum Depression</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression , Postpartum</mesh_term>
	<criteria>Adult female , 1845 year old experience Major Depressive Episode postpartum period begin within first 4 week follow delivery Patient cease lactating , still lactate already fully permanently wean infant ; still actively breastfeed , patient must agree cease give breast milk infant prior study entry Recent history active clinically significant manifestation metabolic , hepatic , renal , hematological , pulmonary , cardiovascular , gastrointestinal , musculoskeletal , dermatological , urogenital , eye , ear , nose throat ( EENT ) disorder Active psychosis Medical history seizure</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Postpartum depression</keyword>
</DOC>